Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Shares (Diluted)

Shares (Diluted) at other companies

AbbVie logo
AbbVieABBV
1.8B+0.1%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
47.2M+33.9%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
51.2M+4.8%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
103.4M+0.9%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
66.1M+8.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
172.7M+3.0%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's shares (diluted)?
Supernus Pharmaceuticals (SUPN) reported shares (diluted) of 57.6M in Q1 2026.
How has Supernus Pharmaceuticals's shares (diluted) changed year-over-year?
Supernus Pharmaceuticals's shares (diluted) increased by 3.2% year-over-year, from 55.9M to 57.6M.
What is the long-term trend for Supernus Pharmaceuticals's shares (diluted)?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's shares (diluted) has grown at a 0.9% compound annual growth rate (CAGR), from 217.6M to 225.5M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.